Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Italy: expenditure for oncology drugs 2017, by category

Expenditure for oncology drugs in Italy in 2017, by category (in million euros)

by Statista Research Department, last edited Sep 26, 2018
Italy: expenditure for oncology drugs 2017, by category This statistic shows the total expenditure for oncology drugs in Italy in 2017, broken down by category. According to data, the spending on monoclonal antibodies amounted to approximately 1.2 billion euros, whereas the expenditure for protein kinase inhibitors reached 778.5 million euros. Moreover, in 2017, 5.3 million euros were addressed to platinum-based drugs.
Show more

Expenditure for oncology drugs in Italy in 2017, by category (in million euros)

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Cancer in Italy"
  • Incidence
  • Screening
  • Mortality
  • Care and treatments
  • Research and fundraising
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.